Skip to content

Optimizing Antiviral Treatment Scheme for Inactive HBsAg Carriers

Optimizing Antiviral Treatment Scheme for Inactive HBsAg Carriers

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017020
Enrollment
Unknown
Registered
2018-07-08
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inactive HBsAg Carriers

Interventions

Treatment group:PEG-IFN135µg/W, HBsAg50IU/ml at 24 week, stop treatment
Control group:no treatment

Sponsors

Beijing You'an Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The diagnosis of inactive HBsAg carriers was consistent with the 2015 Chronic Hepatitis B Prevention Guide. HBsAg positive >2 years, HBsAg<200IU/ml,HBeAg negative, HBV DNA<20IU/ml. ALT level is normal. Ultrasound B or Fibroscan did not indicate cirrhosis.No antiviral treatment within one year.

Exclusion criteria

Exclusion criteria: (1) Patients with HAV, HCV, HDV, HEV infection and autoimmune liver disease; (2) Pregnancy and lactation women and patients who are preparing to give birth in the near future; (3) Severe liver dysfunction or decompensatory cirrhosis; (4) History of serious heart disease, including unstable or uncontrolled heart disease within six months; (5) history of mental illness; (6) uncontrollable epilepsy; (7) alcoholic or drug addict; (8) Uncontrolled diabetes, hypertension, thyroid diseases, retinopathy, autoimmune diseases, etc.; (9) Neutrophils51umol/L.

Design outcomes

Primary

MeasureTime frame
HBsAg;

Countries

China

Contacts

Public ContactCao Zhenhuan

Beijing You'an Hospital, Capital Medical University

caozhenhuanyu@aliyun.com+86 13810248004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026